Georges Hajj, MD
Interventional Cardiology · Kansas City, KSNPI 1619175114
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (39.9%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. 15 manufacturers reported payments, led by Abbott at 44.6% of the total. 2025 is the largest year on record at $2,335, 7.3 times the $318 reported in 2019. That places this record below the midpoint for interventional cardiology clinicians in KS, where the typical reported total is $8,846.
Across 39 payments — averaging $120.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$2K
- Medtronic$2K
- Abiomed$150
- Philips North America LLC$133
- Novartis$122
- Siemens Medical Solutions USA, Inc.$94
- plus $363 from 9 others
What the payments were for
- Speaking & faculty fees$1,50032%
- Travel & lodging$1,32028%
- Food & beverage$1,87540%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 12 | $2,093 |
| Medtronic(2 entities) | 7 | $1,741 |
| Abiomed | 1 | $150 |
| Philips North America LLC | 2 | $133 |
| Novartis | 1 | $122 |
| Siemens Medical Solutions USA, Inc. | 1 | $94 |
| Janssen Scientific Affairs, LLC | 1 | $92 |
| Pfizer | 4 | $79 |
| E.r. Squibb & Sons, L.L.C. | 3 | $46 |
| Amgen | 2 | $35 |
| Shockwave Medical, Inc | 1 | $25 |
| Boston Scientific | 1 | $24 |
| Getinge USA Sales, LLC | 1 | $24 |
| W. L. Gore & Associates, Inc. | 1 | $21 |
| Avinger Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- OPTIS$1,826
- Impella$150
- ENTRESTO$122
- SYMPLICITY G3$121
- (BQ9) Coronary IVUS$120
How this compares
$4,696 in reported general payments places this provider in the 30th percentile of 55 interventional cardiology providers in Kansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Repatha SureclickEvolocumab | 140 | $90,619 |
| EliquisApixaban | 50 | $52,852 |
| Praluent PenAlirocumab | 37 | $20,587 |
| Rosuvastatin Calcium | 149 | $1,957 |
| Ezetimibe | 71 | $1,369 |
| Metoprolol Succinate | 89 | $1,161 |
| Atorvastatin Calcium | 104 | $1,070 |
| Enoxaparin Sodium | 12 | $854 |
| Losartan Potassium | 68 | $727 |
| Carvedilol | 56 | $476 |
| Amlodipine Besylate | 120 | $458 |
| Lisinopril | 46 | $240 |
| Lidocaine-PrilocaineLidocaine/Prilocaine | 13 | $235 |
| Hydralazine Hcl | 17 | $217 |
| Potassium Chloride | 14 | $175 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $79 | $52,85250 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 55 interventional cardiology providers in Kansas.
Other interventional cardiology in Kansas City
- Anthony SpaedyKansas City$385K
- Prasad GunasekaranKansas City$76K
- Kamal GuptaKansas City$46K
- Mark WileyKansas City$39K
- John SerfasKansas City$31K
- Venkat PasnooriKansas City$21K
- Peter TadrosKansas City$20K
- Eric HockstadKansas City$15K
- Ashwani MehtaKansas City$4K
- Maheedhar GedelaWichita$54K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.